Introduction: Coronary slow flow (CSF) is a condition characterized by impaired blood flow rates in the coronary arteries. It can result in severe cardiovascular outcomes. There is no sufficient evidence regarding the certain etiology and reversibility of slow flow patterns and changes in frame counts with long-term management. Methods: We retrospectively enrolled 48 patients with chronic coronary syndrome and CSF who underwent a second angiography. A corrected coronary frame rate (CFR) >27 was defined as CSF. We created 3 groups according to the change in CSF status as the improved, not changed, and worsened groups. We compared the CFR and CSF status of the patients between the first and second angiographies within a median of 2.6 years. Results: We determined a nonsignificant change in cCFR in left anterior descending (LAD) artery (34.4 [18.9] vs. 31.59 [10.3], p = 0.35), circumflex (Cx) artery (42.84 [12.56] vs. 40.66 [13.2], p = 0.35), and right coronary artery (RCA) (57.80 [30.13] vs. 50.32 [19.5], p = 0.11). In the comparison of CSF status of LAD (75% vs. 63%, p = 0.27), Cx (96% vs. 83%, p = 0.09), RCA (94% vs. 94%, p = 1.0) between first and second angiographies, there was no significant change. In the comparison of the 3 groups according to the improvement of CSF status, there was no significant difference in demographic features, change in laboratory parameters, and time between the groups. Conclusion: There was no significant change in the median CFR and CSF status in the overall group between the two angiographies after 3 years.

Journal Section:
Cardiovascular Imaging: Research Article
Keywords:
Coronary slow flow, Chronic coronary syndrome, Frame count, Frame rates
1.
Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ, Giugliano RP, et al. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999;34(4):974–82.
https://doi.org/10.1016/S0735-1097(99)00335-6
2.
Wang X, Nie SP. The coronary slow flow phenomenon: characteristics, mechanisms and implications. Cardiovasc Diagn Ther. 2011;1(1):37–43.
https://doi.org/10.3978/j.issn.2223-3652.2011.10.01
3.
Mangieri E, Macchiarelli G, Ciavolella M, Barillà F, Avella A, Martinotti A, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996;37(4):375–81.
https://doi.org/10.1002/(SICI)1097-0304(199604)37:4%3c375::AID-CCD7%3e3.0.CO;2-8
4.
Ghaffari S, Tajlil A, Aslanabadi N, Separham A, Sohrabi B, Saeidi G, et al. Clinical and laboratory predictors of coronary slow flow in coronary angiography. Perfusion. 2017 Jan;32(1):13–9.
https://doi.org/10.1177/0267659116659918
5.
Horjeti B, Goda A. Acute ischemia manifestation in a patient with coronary slow flow phenomenon. J Electrocardiol. 2012;45(3):277–9.
https://doi.org/10.1016/j.jelectrocard.2011.07.003
6.
Saya S, Hennebry TA, Lozano P, Lazzara R, Schechter E. Coronary slow flow phenomenon and risk for sudden cardiac death due to ventricular arrhythmias: a case report and review of literature. Clin Cardiol. 2008;31(8):352–5.
https://doi.org/10.1002/clc.20266
7.
Karataş MB, Şahan E, Özcan KS, Çanga Y, Güngör B, Onuk T, et al. Anxiety, depression, and general psychological distress in patients with coronary slow flow. Arq Bras Cardiol. 2015;105(4):362–70.
https://doi.org/10.5935/abc.20150092
8.
Henein MY, Vancheri F. Defining coronary slow flow. Angiology. 2021;72(9):805–7.
https://doi.org/10.1177/00033197211007702
9.
Beltrame JF. Defining the coronary slow flow phenomenon. Circ J. 2012;76(4):818–20.
https://doi.org/10.1253/circj.CJ-12-0205
10.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.
https://doi.org/10.1093/eurheartj/ehz425
11.
Gibson CM, Cannon CP, Daley WL, Dodge JTJr, Alexander BJr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996 Mar;93(5):879–88.
https://doi.org/10.1161/01.CIR.93.5.879
12.
Dutta U, Sinha A, Demir OM, Ellis H, Rahman H, Perera D. Coronary slow flow is not diagnostic of microvascular dysfunction in patients with angina and unobstructed coronary arteries. J Am Heart Assoc. 2023;12(1):e027664.
https://doi.org/10.1161/JAHA.122.027664
13.
Fragasso G, Chierchia SL, Arioli F, Carandente O, Gerosa S, Carlino M, et al. Coronary slow-flow causing transient myocardial hypoperfusion in patients with cardiac syndrome X: long-term clinical and functional prognosis. Int J Cardiol. 2009;137(2):137–44.
https://doi.org/10.1016/j.ijcard.2008.06.070
14.
Altun I, Akin F, Kose N, Sahin C, Kirli I. Predictors of slow flow in angiographically normal coronary arteries. Int J Clin Exp Med. 2015;8(8):13762–8.
15.
Aciksari G, Cetinkal G, Kocak M, Atici A, Celik FB, Caliskan M. The relationship between triglyceride/high-density lipoprotein cholesterol ratio and coronary slow-flow phenomenon. Int J Cardiovasc Imaging. 2022;38(1):5–13.
https://doi.org/10.1007/s10554-021-02387-w
16.
Hawkins BM, Stavrakis S, Rousan TA, Abu-Fadel M, Schechter E. Coronary slow flow: prevalence and clinical correlations. Circ J. 2012;76(4):936–42.
https://doi.org/10.1253/circj.CJ-11-0959
17.
Madak N, Nazlı Y, Mergen H, Aysel S, Kandaz M, Yanık E, et al. Acute phase reactants in patients with coronary slow flow phenomenon Koroner yavaş akım fenomeni olan hastalarda akut faz reaktanları. Anadolu Kardiyol Derg. 2010;10(5):416–20.
https://doi.org/10.5152/akd.2010.139
18.
Beltrame JF, Turner SP, Leslie SL, Solomon P, Freedman SB, Horowitz JD. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J Am Coll Cardiol. 2004;44(1):57–62.
https://doi.org/10.1016/j.jacc.2004.03.055
19.
Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J. 2003 Jul;146(1):84–90.
https://doi.org/10.1016/S0002-8703(03)00124-8
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.